Onglyza receives positive opinion in Europe for type 2 diabetes
Tuesday, June 30, 2009 10:00 IST Paris
Bristol-Myers Squibb Company and AstraZeneca announced that their marketing authorization application for Onglyza (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP)